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Clinical PerspectiveWhat Is New?This is the first study to test the association between broad Wnt pathway gene expression and subclinical cardiovascular disease measures in a population‐based sample.We found that expression of 2 Wnt genes (*APC* and *TCF4*) in peripheral blood samples showed association with pulse‐wave velocity independent of traditional cardiovascular disease risk factors.Because pulse‐wave velocity is a marker of several changes in the arterial wall, such as cellular hyperplasia, fibrosis, and calcification, further research is needed to determine in what capacity Wnt signaling may be functioning in arterial stiffness and cardiovascular disease.What Are the Clinical Implications?These findings in humans add further evidence to basic research experiments that have explored the role of Wnt signaling in the vasculature.The Wnt pathway gene expression profile, and in particular expression of *APC* and *TCF4*, may have clinical application as biomarkers for identifying individuals at risk of cardiovascular disease and/or progression.Also, because Wnt signaling has many regulatory roles, any therapeutic targets of the Wnt pathway should also define its potential impact on the cardiovascular system.

Introduction {#jah34745-sec-0008}
============

Experiments in animals and in vitro models implicate the Wnt pathway in cardiac development,[1](#jah34745-bib-0001){ref-type="ref"}, [2](#jah34745-bib-0002){ref-type="ref"}, [3](#jah34745-bib-0003){ref-type="ref"} vascular calcification,[4](#jah34745-bib-0004){ref-type="ref"}, [5](#jah34745-bib-0005){ref-type="ref"}, [6](#jah34745-bib-0006){ref-type="ref"} and atherosclerosis.[7](#jah34745-bib-0007){ref-type="ref"}, [8](#jah34745-bib-0008){ref-type="ref"}, [9](#jah34745-bib-0009){ref-type="ref"} Fibrosis and large, dense calcifications occur in the vessel wall[10](#jah34745-bib-0010){ref-type="ref"} to stabilize atherosclerotic plaques and in the medial layer of the artery as an early hallmark of the arteriosclerotic process, manifesting as arterial stiffening.[8](#jah34745-bib-0008){ref-type="ref"} Previous studies have implicated Wnt pathway genes and proteins in vascular fibrosis and/or calcification, including Dkk1 (dickopf 1),[11](#jah34745-bib-0011){ref-type="ref"} Wnt2,[12](#jah34745-bib-0012){ref-type="ref"} Wnt3a,[12](#jah34745-bib-0012){ref-type="ref"}, [13](#jah34745-bib-0013){ref-type="ref"}, [14](#jah34745-bib-0014){ref-type="ref"} Wnt5a,[12](#jah34745-bib-0012){ref-type="ref"} Wnt7a,[13](#jah34745-bib-0013){ref-type="ref"}, [15](#jah34745-bib-0015){ref-type="ref"} and Wnt7b.[11](#jah34745-bib-0011){ref-type="ref"}, [12](#jah34745-bib-0012){ref-type="ref"}, [13](#jah34745-bib-0013){ref-type="ref"}, [15](#jah34745-bib-0015){ref-type="ref"} It is not currently feasible to measure these pathological features of the vessel wall tissue in population‐based studies; therefore, noninvasive, subclinical cardiovascular disease (CVD) measures, such as arterial pulse‐wave velocity (PWV), are typically used as proxies for these underlying pathological features.[16](#jah34745-bib-0016){ref-type="ref"}, [17](#jah34745-bib-0017){ref-type="ref"}

Despite the wealth of in vitro data, studies on the Wnt pathway and CVD in humans have remained sparse and considered only a few of the many components of the complex Wnt signaling pathway. For example, the existing studies on the Wnt pathway and arterial stiffness are focused on protein‐based assays of circulating Dkk1[18](#jah34745-bib-0018){ref-type="ref"}, [19](#jah34745-bib-0019){ref-type="ref"}, [20](#jah34745-bib-0020){ref-type="ref"} and sclerostin.[19](#jah34745-bib-0019){ref-type="ref"}, [20](#jah34745-bib-0020){ref-type="ref"}, [21](#jah34745-bib-0021){ref-type="ref"}, [22](#jah34745-bib-0022){ref-type="ref"}, [23](#jah34745-bib-0023){ref-type="ref"} These studies have generally found a significant association with arterial stiffness, but research is still lacking on many facets of the Wnt pathway, particularly in individuals of African ancestry who are at high risk of hypertensive vascular disease.[24](#jah34745-bib-0024){ref-type="ref"} In the current study, we comprehensively assessed Wnt pathway gene expression in peripheral blood and arterial stiffness in African Caribbean men who have a high burden of hypertension and arterial stiffening.[25](#jah34745-bib-0025){ref-type="ref"}

Methods {#jah34745-sec-0009}
=======

Tobago Health Study {#jah34745-sec-0010}
-------------------

The data that support the findings of this study are available from the corresponding author on reasonable request.** **All men included in this analysis were from the THS (Tobago Health Study), a population‐based, prospective cohort study of community‐dwelling men aged ≥40 years, residing on the Caribbean island of Tobago.[26](#jah34745-bib-0026){ref-type="ref"} Participants for the THS were recruited without regard to health status, and men were eligible if they were ambulatory, not terminally ill, and without a bilateral hip replacement. Men from Tobago are of African ancestry, with low European admixture (\<6%).[27](#jah34745-bib-0027){ref-type="ref"} A follow‐up visit for the THS, conducted from 2014 to 2017, included assessment of arterial stiffness using brachial‐ankle PWV. At this visit, men underwent assessment for PWV (N=795), and a random subset of 368 men were selected to have Wnt pathway gene expression measured and form the basis for the current analysis. Standard clinical examinations and interviewer‐administered health history questionnaires were administered at all THS visits. Written informed consent was obtained from each man using forms and procedures approved by the University of Pittsburgh Institutional Review Board, the US Surgeon General\'s Human Use Review Board, and the Tobago Division of Health and Social Services Institutional Review Board.

Brachial‐Ankle PWV {#jah34745-sec-0011}
------------------

Arterial stiffness was measured as brachial‐ankle PWV using a noninvasive, waveform analyzer (Colin‐VP1000; Omron, Japan/WaveNexus, TX), as previously described.[28](#jah34745-bib-0028){ref-type="ref"} Briefly, after 10 minutes of rest in a supine position, occlusion/monitoring cuffs were placed at standardized locations on lightly clothed arms and bare ankles. Then, ECG electrodes were placed on the arms and ankles, while a phonocardiogram was placed on the left edge of the sternum to audibly detect heart sounds. The cuffs were connected to a plethysmographic sensor and an oscillometric pressure sensor, which recorded volume pressure waveforms and blood pressure, respectively. The volume pressure waveforms were collected at the arm (brachial artery) and ankle (tibial artery) over a total sampling time of 10 seconds, with automatic gain analysis and quality adjustment. Brachial‐ankle PWV was calculated as follows: (distance between arterial sites in cm)/(time between the foot of the waveforms in s). The distance was measured using a height‐based formula[17](#jah34745-bib-0017){ref-type="ref"} that accounts for the opposite direction of blood flow by subtracting the distance from the brachial artery to the heart. PWV was measured twice on both the right and left sides, and mean PWV was used in this analysis as the average between the 2 left and 2 right PWV measures. Although brachial‐ankle PWV is considered a mixed measure of arterial stiffness because it takes into account both central and peripheral arteries, it has been shown to be more highly correlated with central PWV[29](#jah34745-bib-0029){ref-type="ref"} than peripheral PWV,[30](#jah34745-bib-0030){ref-type="ref"} and is also predictive of pulse‐pressure[31](#jah34745-bib-0031){ref-type="ref"} and cardiovascular events.[28](#jah34745-bib-0028){ref-type="ref"}, [32](#jah34745-bib-0032){ref-type="ref"}

Other Characteristics {#jah34745-sec-0012}
---------------------

Demographic, health history, and anthropomorphic characteristics were assessed by trained staff using interview and clinical examinations. Body weight was measured to the nearest 0.1 kg on a balance beam scale and standing height was measured to the nearest 0.1 cm using a wall‐mounted stadiometer, both without participants wearing shoes. Body mass index was calculated as body weight in kilograms divided by standing height in meters squared. Blood pressure was measured 3 times in a seated position with 10 minutes of rest in between readings using an automated sphygmomanometer (Omron). For this analysis, we present the mean of the second and third readings as average systolic and diastolic blood pressures (SBP and DBP, respectively). Current use of antihypertension medications was assessed at the time of participant interview. Hypertension was defined as mean SBP ≥140 mm Hg, DBP ≥90 mm Hg, or self‐reported use of antihypertension medication. Current self‐reported use of lipid‐lowering therapies was assessed at the time of participant interview. Smoking status was classified as current or not. Alcohol consumption is limited in this cohort sample and was, therefore, coded as consuming \>3 drinks per week (yes/no) to identify individuals with greater than average cohort alcohol intake. We modeled sedentary behavior as usually watching ≥14 hours of TV per week versus not.

Nanostring nCounter Analysis of Wnt Pathway Gene Expression {#jah34745-sec-0013}
-----------------------------------------------------------

Because there have been no previous studies of Wnt pathway gene expression in humans, Wnt pathway genes ([Table S1](#jah34745-sup-0001){ref-type="supplementary-material"}) were selected for inclusion on a custom gene expression panel based on expression bioinformatics databases, such as the Gene Expression Atlas (<http://www.ebi.ac.uk>), and required expression in the vasculature and/or atherosclerotic plaques. We also performed a thorough literature review, including review of model organism and in vitro experiment studies, to select Wnt pathway genes that were most likely to be associated with CVD (N=43 selected genes). Gene expression was measured using a custom CodeSet for the selected Wnt genes in the Nanostring nCounter Analysis System (NanoString Technologies, Seattle, WA).[33](#jah34745-bib-0033){ref-type="ref"} The NanoString technology uses a digital color‐coded barcode tag with single‐molecule imaging that can detect and count hundreds of unique transcripts per reaction. The correlation between technical replicates using the nCounter system is 0.999, and it has coefficients of variation between 3% and 15%, depending on the number of mRNA transcripts per cell. In addition to the 43 Wnt pathway genes, we included 3 reference or housekeeping genes ([Table S1](#jah34745-sup-0001){ref-type="supplementary-material"}) to control for background signal.

RNA Extraction and Quantification of Gene Expression {#jah34745-sec-0014}
----------------------------------------------------

Peripheral blood was drawn at the time of the visit into PAXgene Blood RNA collection tubes (PreAnalytiX, Hombrechtikon, Switzerland), according to manufacturer\'s protocol. Samples were frozen at −80°C and shipped to the University of Pittsburgh overnight on dry ice. Samples were stored at −80°C until extraction and isolation, which was conducted using the PAXgene Blood RNA kit (PreAnalytiX), according to the manufacturer\'s protocol on the whole peripheral blood samples. No cellular fractionation was performed. All extracted samples were assessed for RNA sample quality and concentration using DropSense96 quantification (Trinean NV/SA, Gentbrugge, Belgium). For the nCounter gene expression analysis, 100 ng of total mRNA was aliquoted at 20 ng/μL for each participant. The data resulting from the nCounter system are expressed as number of molecules (ie, counts), per standardized input of sample. The resulting Wnt gene expression counts were normalized to 3 housekeeping genes ([Table S1](#jah34745-sup-0001){ref-type="supplementary-material"}) after removing the background signal using an automated feature of the nSolver software (NanoString Technologies). Only genes with detectable expression in the peripheral blood were used in the analysis.

Statistical Analysis {#jah34745-sec-0015}
--------------------

Brachial‐ankle PWV and Wnt gene expression counts were assessed for normality and transformed to a normal distribution using a log transformation, as needed. Means and SDs or frequencies were calculated for covariates and gene expression counts in the total sample and stratified by high versus low PWV status, on the basis of splitting the sample at the median PWV (1586 cm/s). Differences in characteristics between high and low PWV status were tested with *t* tests, Wilcoxon rank‐sum tests, or χ^2^ tests, as appropriate.

We used multiple linear regression to test the association of individual Wnt gene expression counts (predictors) with PWV (outcome) and reported as the effect on PWV per 1‐SD greater expression. We provide unadjusted, age‐adjusted, and fully adjusted models that adjusted for age, height, weight, SBP, DBP, antihypertensive medication use, resting heart rate, lipid‐lowering medication use, current smoking, alcohol use, and sedentary behavior. All analyses were performed using SAS, version 9.4 (Cary, NC).

To determine if there was underlying structure in the Wnt pathway gene expression profile of these men, we also conducted exploratory factor analysis using maximum likelihood methods with direct varimax rotation using proc factor in SAS. We retained the 3‐factor solution based on model fit statistics and required gene expressions to load at ≥\|0.3\| to be included in any factor. Similar to the individual Wnt gene expression analysis, we used multiple linear regression to test the association of individual Wnt gene expression factors (predictors) with PWV (outcome) and reported results as the effect on PWV per 1‐SD greater Wnt gene expression factor. We provide unadjusted, age‐adjusted, and fully adjusted models that adjusted for age, height, weight, SBP, DBP, antihypertensive medication use, heart rate, lipid‐lowering medication use, current smoking, alcohol use, and sedentary behavior.

Results {#jah34745-sec-0016}
=======

Study Characteristics {#jah34745-sec-0017}
---------------------

Men were aged 63.8 years on average (range, 51--89 years; Table [1](#jah34745-tbl-0001){ref-type="table"}) and 65% had hypertension. Mean brachial‐ankle PWV was 1586 cm/s (interquartile range, 1388--1841 cm/s). Men with high PWV based on a median split were older, had higher blood pressures and heart rate, and were more likely to be using lipid‐lowering medications compared with those with low PWV (all *P*\<0.01). However, they also tended to be shorter and weigh less (both *P*\<0.02; Table [1](#jah34745-tbl-0001){ref-type="table"}).

###### 

Characteristics of the Study Population by Median Arterial Stiffness

  Characteristics                                    Overall (N=368)     Low PWV (N=183)     High PWV (N=185)    *P* Value[a](#jah34745-note-0003){ref-type="fn"}
  -------------------------------------------------- ------------------- ------------------- ------------------- --------------------------------------------------
  Age, y                                             63.8±8.5            60.4±6.8            67.1±8.7            \<0.001
  Height, cm                                         175.2±7.0           176.6±6.7           173.8±6.9           \<0.001
  Weight, kg                                         84.7±15.1           86.5±15.6           82.8±14.3           0.018
  BMI, kg/m^2^                                       27.5±4.4            27.7±4.5            27.4±4.3            0.584
  SBP, mm Hg                                         142.8±21.7          134.4±17.6          151.4±22.1          \<0.001
  DBP, mm Hg                                         79.7±12.0           77.2±10.4           82.4±13.0           \<0.001
  Hypertension, %                                    65.3                48.1                83.1                \<0.001
  HR, bpm                                            67.5±12.5           64.0±11.1           71.0±12.8           \<0.001
  Current smoking, %                                 6.2                 8.1                 4.4                 0.139
  Consume \>4 alcohol drinks/wk, %                   14.4                11.9                16.9                0.168
  Watch \>14 h of TV/wk, %                           51.1                46.7                55.7                0.085
  Antihypertensive medication use, %                 43.1                32.4                54.1                \<0.001
  Cholesterol‐lowering medication use, %             15.7                10.3                20.8                0.005
  PWV, cm/s[a](#jah34745-note-0003){ref-type="fn"}   1586 (1388--1841)   1388 (1286--1478)   1841 (1720--2046)   NA

Characteristics shown as mean±SD or percentage, as appropriate, and as median (interquartile range) for PWV. BMI indicates body mass index; bpm, beats per minute; DBP, diastolic blood pressure; HR, heart rate; NA, not applicable; PWV, pulse‐wave velocity; SBP, systolic blood pressure.

Unadjusted *P* values shown from *t* tests of the difference in participant characteristics by median split PWV.

Wnt Pathway Peripheral Blood Gene Expression {#jah34745-sec-0018}
--------------------------------------------

Of the 43 tested Wnt genes, 14 were detected in peripheral blood samples (Table [2](#jah34745-tbl-0002){ref-type="table"}; [Table S2](#jah34745-sup-0001){ref-type="supplementary-material"}). Genes with the greatest expression counts included the following: β catenin 1 (*CTNNB1*; mean count, 1270), transcription factor 7 (*TCF7*; mean count, 984), lymphoid enhancer binding factor 1 (*LEF1*; mean count, 910), glycogen synthase kinase 3β (*GSK3B*; mean count, 853), and axin 1 (*AXIN1*; mean count, 499). In unadjusted analyses, men with high PWV based on a median split had greater expression of adenomatous polyposis coli regulator of Wnt signaling pathway (*APC*), *AXIN1*, cadherin 2 (*CDH2*), *CTNNB1*, and *GSK3B*, and lower expression of axin 2 (*AXIN2*) and transcription factor 4 (*TCF4*; all *P*\<0.05; Table [2](#jah34745-tbl-0002){ref-type="table"}) compared with men with low PWV.

###### 

Distribution of Normalized Wnt Gene Expression Counts and Exploratory Factors by Median Arterial Stiffness

  Wnt Gene            Overall (N=368)   Low PWV (N=185)   High PWV (N=183)   Difference, %   *P* Value[a](#jah34745-note-0005){ref-type="fn"}
  ------------------- ----------------- ----------------- ------------------ --------------- --------------------------------------------------
  *APC*, counts       157.4±35.6        152.5±33.7        162.2±36.8         6.2             0.012
  *AXIN1*, counts     499.2±93.4        487.3±83.8        511.2±101.2        4.8             0.047
  *AXIN2*, counts     82.7±33.7         85.6±31.8         79.9±35.5          −6.9            0.012
  *CDH2*, counts      18.7±6.3          18.2±6.8          19.2±5.7           5.3             0.018
  *CTNNB1*, counts    1269.5±152.8      1243.2±146.9      1296.1±154.8       4.2             0.008
  *FZD1*, counts      26.3±9.0          26.0±8.7          26.4±9.3           1.5             0.780
  *FZD6*, counts      20.2±6.0          19.9±5.6          20.5±6.3           3.0             0.299
  *GSK3B*, counts     852.6±159.0       825.4±147.1       879.7±166.5        6.4             0.005
  *KREMEN1*, counts   119.2±89.2        116.3±85.6        121.6±92.8         4.4             0.397
  *LEF1*, counts      910.2±318.2       925.7±302.1       895.0±334.5        −3.4            0.102
  *SFRP2*, counts     19.9±8.8          19.6±9.8          20.2±7.7           3.0             0.061
  *TCF4*, counts      110.5±39.5        116.1±43.9        104.8±33.6         −10.2           0.009
  *TCF7*, counts      984.3±318.5       994.8±312.5       975.1±325.3        −2.0            0.248
  *WNT16*, counts     20.3±14.0         21.1±19.1         19.4±5.4           −8.4            0.439

Characteristics shown as mean±SD and as the percentage difference in Wnt gene expression counts in high compared with low PWV men, as categorized by a median split. *APC* indicates adenomatous polyposis coli regulator of Wnt signaling pathway; *AXIN*, axin; *CDH2*, cadherin 2; *CTNNB1*, catenin β 1; *FZD*, frizzled class receptor; *GSK3B*, glycogen synthase kinase 3β; *KREMEN1*, kringle‐containing transmembrane protein 1; *LEF1*, lymphoid enhancer binding factor 1; PWV, pulse‐wave velocity; *SFRP2*, secreted frizzled related protein 2; *TCF*, transcription factor; *WNT16*, Wnt family member 16.

Unadjusted *P* values from Wilcoxon nonparametric tests of a difference not equal to 0.

Wnt Pathway Gene Expression and Arterial Stiffness {#jah34745-sec-0019}
--------------------------------------------------

In age‐adjusted models, men with high PWV had greater expression of *APC* and lower expression of *AXIN2*,*LEF1*, and *TCF4* (all *P*\<0.05; Table [3](#jah34745-tbl-0003){ref-type="table"}). After additional adjustment for height, weight, SBP, DBP, antihypertensive medication use, heart rate, lipid‐lowering medication use, current smoking, alcohol use, and sedentary behavior, both *APC* and *TCF4* expression remained significantly associated with PWV in opposite directions (*P*=0.01 for both; *APC* positive direction, *TCF4* negative direction). In addition, greater *GSK3B* expression was associated with greater PWV (*P*=0.048). When *APC*,*TCF4*, and *GSK3B* were entered together in the fully adjusted model, only *APC* and *TCF4* remained significantly associated with PWV (Table [4](#jah34745-tbl-0004){ref-type="table"}). Specifically, a 1‐SD greater expression of *APC* was associated with 44.4 cm/s greater PWV (*P*=0.035), while at the same time, a 1‐SD lower expression of *TCF4* was associated with 43.2 cm/s greater PWV (*P*=0.003). The effects of *APC* and *TCF4* expression were similar in magnitude to a ≈3‐year higher or lower age, respectively.

###### 

Association of Individual Wnt Gene Expression Counts With Arterial Stiffness

  Wnt Gene    Unadjusted   Age Adjusted   Fully Adjusted[a](#jah34745-note-0007){ref-type="fn"}                     
  ----------- ------------ -------------- ------------------------------------------------------- --------- ------- -------
  *APC*       68.7         \<0.001        41.7                                                    0.032     42.3    0.010
  *AXIN1*     35.7         0.051          6.2                                                     0.709     10.3    0.463
  *AXIN2*     −51.1        0.003          −35.3                                                   0.020     −8.9    0.487
  *CDH2*      33.4         0.055          15.6                                                    0.289     2.3     0.766
  *CTNNB1*    46.7         0.016          10.3                                                    0.655     18.9    0.235
  *FZD1*      23.4         0.247          5.7                                                     0.831     9.7     0.548
  *FZD6*      23.4         0.233          18.1                                                    0.308     14.4    0.344
  *GSK3B*     63.2         0.002          29.4                                                    0.157     33.2    0.048
  *KREMEN1*   41.8         0.037          17.5                                                    0.397     22.6    0.179
  *LEF1*      −63.2        \<0.001        −34.8                                                   0.049     −11.3   0.600
  *SFRP2*     18.0         0.294          −0.5                                                    0.967     −1.4    0.995
  *TCF4*      −73.1        \<0.001        −61.2                                                   \<0.001   −37.7   0.007
  *TCF7*      −59.8        0.002          −33.3                                                   0.070     −9.7    0.729
  *WNT16*     −1.0         0.888          −1.6                                                    0.845     −8.5    0.457

Values shown as the β coefficient for pulse‐wave velocity per SD greater Wnt gene expression. *APC* indicates adenomatous polyposis coli regulator of Wnt signaling pathway; *AXIN*, axin; *CDH2*, cadherin 2; *CTNNB1*, catenin β 1; *FZD*, frizzled class receptor; *GSK3B*, glycogen synthase kinase 3β; *KREMEN1*, kringle‐containing transmembrane protein 1; *LEF1*, lymphoid enhancer binding factor 1; *SFRP2*, secreted frizzled related protein 2; *TCF*, transcription factor; *WNT16*, Wnt family member 16.

Fully adjusted models include adjustment for age, height, weight, systolic blood pressure, diastolic blood pressure, antihypertensive medication use, heart rate, lipid‐lowering medication use, current smoking, alcohol use, and sedentary behavior.

###### 

Fully Adjusted Effects of Wnt Pathway Gene Expression and Traditional Cardiovascular Risk Factors on Arterial Stiffness

  Covariate                                           Unit          β, cm/s   \% PWV Difference Explained   *P* Value
  --------------------------------------------------- ------------- --------- ----------------------------- -----------
  Age[a](#jah34745-note-0009){ref-type="fn"}          5 y           69.2      4.2                           \<0.001
  Height[a](#jah34745-note-0009){ref-type="fn"}       7.0 cm        −27.1     −1.6                          0.062
  Weight[a](#jah34745-note-0009){ref-type="fn"}       15.1 kg       −24.2     −1.5                          0.213
  SBP[a](#jah34745-note-0009){ref-type="fn"}          21.7 mm Hg    116.8     7.1                           \<0.001
  DBP[a](#jah34745-note-0009){ref-type="fn"}          12.0 mm Hg    3.9       0.2                           0.710
  Antihypertensive medication use                     1             −10.1     −0.6                          0.789
  Heart rate[a](#jah34745-note-0009){ref-type="fn"}   12.5 bpm      89.7      5.4                           \<0.001
  Current smoking                                     1             −61.5     −3.7                          0.276
  Consume \>4 alcohol drinks/wk                       1             68.1      4.1                           0.088
  Watch \>14 hours of TV/wk                           1             9.5       0.6                           0.722
  Cholesterol‐lowering medication use                 1             106.7     6.5                           0.012
  *APC* [a](#jah34745-note-0009){ref-type="fn"}       35.6 count    44.4      2.7                           0.035
  *GSK3B* [a](#jah34745-note-0009){ref-type="fn"}     159.0 count   5.5       0.3                           0.892
  *TCF4* [a](#jah34745-note-0009){ref-type="fn"}      39.5 count    −43.2     −2.6                          0.003

*APC* indicates adenomatous polyposis coli regulator of Wnt signaling pathway; DBP, diastolic blood pressure; *GSK3B*, glycogen synthase kinase 3β; PWV, pulse‐wave velocity; SBP, systolic blood pressure; *TCF4*, transcription factor 4.

Results shown per 1‐SD greater covariate value, except for age, which was modeled as per a 5‐year greater age.

Exploratory Factor Analysis of Wnt Gene Expression and Arterial Stiffness {#jah34745-sec-0020}
-------------------------------------------------------------------------

Exploratory factor analysis identified 3 factors underlying the Wnt gene expression profile (Table [5](#jah34745-tbl-0005){ref-type="table"}). All factors were normalized to have a mean of 0 with an SD of 1 unit. The first factor, which explained 19% of the variance in Wnt gene expression, consisted of *GSK3B*,*CTNNB1*,*APC*,*KREMEN1* (kringle‐containing transmembrane protein 1), and *AXIN1*. The second factor, which explained the most variance in Wnt gene expression at 28%, consisted of *TCF4*,*LEF1*, and *AXIN2*. The third factor, which only explained 2% of the variance in Wnt gene expression, consisted of frizzled class receptor 6 (*FZD6*), *CDH2*,*SFRP2* (secreted frizzled related protein 2), and Wnt family member 16 (*WNT16*). Of note, *FZD1* and *TCF4* did not load onto any factor ≥0.3. These loadings largely reflected the underlying correlation structure between the Wnt genes ([Table S2](#jah34745-sup-0001){ref-type="supplementary-material"}). In fully adjusted analyses of these Wnt gene expression factors and arterial stiffness, factor 1 was significantly associated with greater PWV, such that a 1‐SD greater expression of factor 1 was associated with 34.7‐cm/s greater PWV (*P*=0.03; [Figure](#jah34745-fig-0001){ref-type="fig"}). Although neither factor 2 nor factor 3 was significantly associated with PWV in fully adjusted models, higher factor 2 was associated with lower PWV in unadjusted (*P*=0.002) and age‐adjusted models (*P*=0.04; [Figure](#jah34745-fig-0001){ref-type="fig"}).

###### 

Exploratory Factor Analysis Loadings

  Wnt Gene                                                       Factor 1   Factor 2   Factor 3
  -------------------------------------------------------------- ---------- ---------- ----------
  *APC*                                                          0.723      ...        ...
  *AXIN1*                                                        0.520      ...        ...
  *AXIN2*                                                        ...        0.807      ...
  *CDH2*                                                         ...        ...        0.620
  *CTNNB1*                                                       0.796      ...        ...
  *FZD1* [a](#jah34745-note-0011){ref-type="fn"}                 ...        ...        ...
  *FZD6*                                                         ...        ...        0.621
  *GSK3B*                                                        0.968      ...        ...
  *KREMEN1*                                                      0.557      ...        ...
  *LEF1*                                                         ...        0.920      ...
  *SFRP2*                                                        ...        ...        0.461
  *TCF4* [a](#jah34745-note-0011){ref-type="fn"}                 ...        ...        ...
  *TCF7*                                                         ...        0.970      ...
  *WNT16*                                                        ...        ...        0.343
  Variance explained, %[b](#jah34745-note-0012){ref-type="fn"}   19.3       28.0       1.9

*APC* indicates adenomatous polyposis coli regulator of Wnt signaling pathway; *AXIN*, axin; *CDH2*, cadherin 2; *CTNNB1*, catenin β 1; *FZD*, frizzled class receptor; *GSK3B*, glycogen synthase kinase 3β; *KREMEN1*, kringle‐containing transmembrane protein 1; *LEF1*, lymphoid enhancer binding factor 1; *SFRP2*, secreted frizzled related protein 2; *TCF*, transcription factor; *WNT16*, Wnt family member 16.

*FZD1* and *TCF4* did not load onto any factor at ≥0.3.

Weighted variance of Wnt gene expression explained by each factor.

![Association of Wnt gene expression factors with arterial stiffness. The graph shows the adjusted β coefficients and SE bars for the difference in pulse‐wave velocity per 1‐SD greater expression of each Wnt pathway gene factor. Unadjusted (black bars), age‐adjusted (dark gray bars), and fully adjusted (light gray bars) models are shown. Fully adjusted models include adjustment for age, height, weight, systolic blood pressure, diastolic blood pressure, antihypertensive medication use, heart rate, lipid‐lowering medication use, current smoking, alcohol use, and sedentary behavior. *APC*, adenomatous polyposis coli regulator of Wnt signaling pathway; *AXIN*, axin; *CDH2*, cadherin 2; *CTNNB1*, catenin β 1; *FZD6*, frizzled class receptor 6; *GSK3B*, glycogen synthase kinase 3β; *Kremen1*, kringle‐containing transmembrane protein 1; *LEF1*, lymphoid enhancer binding factor 1; *SFRP2*, secreted frizzled related protein 2; *TCF7*, transcription factor 7; *WNT16*, Wnt family member 16. ^\$^ *P*=0.07, +*P*\<0.05, \**P*\<0.001.](JAH3-9-e014170-g001){#jah34745-fig-0001}
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==========

This is the first study to comprehensively assess the association of Wnt pathway gene expression and arterial stiffness in humans. We found that of the 43 Wnt mRNAs tested, 14 were detected in peripheral blood from our African ancestry study sample and may suggest that they function in human circulation. Of the detectable mRNAs, 2 (*APC* and *TCF4*) showed significant associations with arterial stiffness, as assessed by PWV, even after accounting for traditional CVD risk factors. These relationships were also identified through exploratory factor analyses. These results highlight the biologic complexity underlying the Wnt pathway\'s effect on the vascular system and the importance of assessing multiple pathway components in determining overall Wnt pathway signaling status.

This direction of effect recapitulates the known Wnt pathway biological features in that some genes lead to upregulation of Wnt pathway target genes, whereas others downregulate it. For example, most of the Wnt pathway genes with positive associations between their expression and PWV, such as those that clustered together in factor 1 (*APC*,*AXIN1*, and *GSK3B*), form a protein complex with β‐catenin (*CTNNB1*; also in factor 1) in the absence of Wnt signaling to prevent the transcription of Wnt target genes.[34](#jah34745-bib-0034){ref-type="ref"} In contrast, most of the Wnt pathway genes with negative associations between their expression and PWV, such as those that clustered together in factor 2 (*LEF1*,*TCF7*, and *AXIN2*) and *TCF4*, generally code for proteins that, in the presence of Wnt signaling, cluster together and allow transcription factors to translocate to the nucleus to upregulate Wnt pathway target genes.[34](#jah34745-bib-0034){ref-type="ref"} Axin‐2 is a slightly different story because its protein form functions to downregulate Wnt signaling,[35](#jah34745-bib-0035){ref-type="ref"} but the gene *AXIN2* is also a target of Wnt signaling[36](#jah34745-bib-0036){ref-type="ref"}; therefore, it makes sense that its gene expression tracks closely with *LEF1* and *TCF7*. Given the cross‐sectional nature of our data, we cannot say for certain whether this Wnt expression pattern caused the arterial stiffness, thereby suggesting that Wnt signaling protects the vessels from stiffening, or whether these data may depict a negative feedback loop that downregulated Wnt signaling, causing arteries to stiffen. Last, Wnt signals via both canonical and noncanonical pathways.[37](#jah34745-bib-0037){ref-type="ref"} Most of the research referenced herein is about the canonical Wnt signaling cascade; however, when canonical signaling is reduced, noncanonical signaling is concomitantly increased and may, in fact, be a significant driver in CVD, as well.[38](#jah34745-bib-0038){ref-type="ref"}, [39](#jah34745-bib-0039){ref-type="ref"} Nonetheless, the results from this study are the first to suggest that Wnt pathway signaling is associated with human arterial stiffness.

Previous studies of the Wnt pathway and arterial stiffness generally studied 1 or 2 circulating Wnt inhibitor proteins, such as SOST (sclerostin) or Dkk1. SOST and Dkk1 reduce Wnt pathway signaling.[34](#jah34745-bib-0034){ref-type="ref"} However, they represent only a single aspect of the complex Wnt signaling pathway. Most,[19](#jah34745-bib-0019){ref-type="ref"}, [20](#jah34745-bib-0020){ref-type="ref"}, [21](#jah34745-bib-0021){ref-type="ref"}, [23](#jah34745-bib-0023){ref-type="ref"} but not all,[18](#jah34745-bib-0018){ref-type="ref"}, [22](#jah34745-bib-0022){ref-type="ref"} of these studies found circulating SOST to be positively associated with greater arterial stiffness, which is in alignment with findings from the current study. However, previous results for Dkk1 were generally null,[19](#jah34745-bib-0019){ref-type="ref"}, [20](#jah34745-bib-0020){ref-type="ref"}, [23](#jah34745-bib-0023){ref-type="ref"} although one showed an inverse relationship.[18](#jah34745-bib-0018){ref-type="ref"} In contrast, the current study used a pathway‐wide approach to obtain a broader view of Wnt pathway gene expression and its potential association with arterial stiffness.

We found that 2 Wnt genes were significantly associated with arterial stiffness: *APC* and *TCF4*. Previous research on *APC* and arterial stiffness is limited, although some studies have implicated *APC* in atherosclerotic fibrous cap stability,[40](#jah34745-bib-0040){ref-type="ref"} cardiac repair[41](#jah34745-bib-0041){ref-type="ref"} and development,[42](#jah34745-bib-0042){ref-type="ref"} hypertrophic cardiomyopathy,[43](#jah34745-bib-0043){ref-type="ref"} and cardiomyocyte proliferation.[44](#jah34745-bib-0044){ref-type="ref"} Because the APC protein is largely intracellular, it has not previously been assessed in population‐based studies and this is the first report of its in vivo expression and potential association with human vascular disease measures.

On the other hand, *TCF4*, which is also known as *TCF7L2*, has a genetic variant (*rs7903146*) that was identified in 2007 as a strong risk factor for diabetes mellitus and impaired fasting glucose.[45](#jah34745-bib-0045){ref-type="ref"} This genetic association has been replicated in many studies and has also been shown to be associated with diabetic coronary artery atherosclerosis[46](#jah34745-bib-0046){ref-type="ref"}, [47](#jah34745-bib-0047){ref-type="ref"} and ankle‐brachial index.[48](#jah34745-bib-0048){ref-type="ref"} To our knowledge, *TCF4* genetic variants have not been studied in relationship to arterial stiffness. The action of *TCF4* in coronary artery disease appears to be through vascular smooth muscle cell plasticity[49](#jah34745-bib-0049){ref-type="ref"}, [50](#jah34745-bib-0050){ref-type="ref"} and proliferation,[51](#jah34745-bib-0051){ref-type="ref"} which could also impact arterial wall stiffness. In sensitivity analyses, we found that the addition of diabetes mellitus to our full model slightly attenuated (≈7%) the reported associations between *TCF4* expression and arterial stiffness, although the magnitude of the relationship was similar and still significant (*P*=0.004; data not shown). Like APC, the TCF4 protein is largely intracellular and has not previously been assessed in population‐based studies, so this report represents a novel finding that extends the known associations of TCF4 and vascular disease to arterial stiffness.

Factor analysis identified 2 main factors that explained most of the variation in Wnt gene expression patterns. Factor 1 appears to consist mostly of genes responsible for Wnt signal transduction, whereas factor 2 appears to consist mostly of genes responsible for transcriptional regulation of Wnt signaling target genes. In addition, factor analysis identified a third factor that only accounted for a small percentage of variation in Wnt gene expression, and appears to consist mostly of genes involved in cell‐surface Wnt signaling. Although factors 1 and 2 were significantly associated with arterial stiffness in minimally adjusted models, only factor 1 was significant in models adjusted for CVD risk factors. Interestingly, the Wnt gene with strongest individual association between its expression and arterial stiffness, *TCF4*, did not load onto any factor at ≥0.3 and it had fairly low levels of correlation to other Wnt genes (maximum, 0.26 with *AXIN2;* [Table S2](#jah34745-sup-0001){ref-type="supplementary-material"}). This may suggest that the strong association of *TCF4* with arterial stiffness may be operating through additional mechanisms other than canonical Wnt signaling.

As with any gene expression study, the results are reflective only of the tissue and population sample they are derived from: in this case, peripheral blood from African ancestry men. We could not perform blood cell sorting or counting for determining the cellular composition of the blood samples, so our results reflect expression profiles of a mixture of circulating cells. However, as our outcome of interest is arterial stiffness, peripheral blood is a reasonable tissue source[52](#jah34745-bib-0052){ref-type="ref"}, [53](#jah34745-bib-0053){ref-type="ref"} given the noninvasive collection method and its constant contact with the vessel wall.[54](#jah34745-bib-0054){ref-type="ref"} We found a large number (29 of 43) of the tested Wnt pathway genes did not have detectable expression, so we cannot comment on their potential association with vascular disease. We also cannot comment on Wnt pathway genes that were not included on this custom array panel, which was designed to include only genes with previous evidence for involvement in CVD processes and/or expression in the vascular wall. It is possible that some of these genes may be expressed and function only in the vessel wall, rather than the circulation.[12](#jah34745-bib-0012){ref-type="ref"}, [13](#jah34745-bib-0013){ref-type="ref"}, [14](#jah34745-bib-0014){ref-type="ref"}, [15](#jah34745-bib-0015){ref-type="ref"} It is also possible that expression profiles may differ by ethnicity, exposures, or physiologic conditions, such as inflammation, which we were unable to control. However, as individuals of African ancestry are at particularly high risk of vascular disease with poor hypertension control, including these THS men,[25](#jah34745-bib-0025){ref-type="ref"} this represents an important population segment for human molecular research. There may be a biologic difference in Wnt expression profiles by sex, as previously reported,[55](#jah34745-bib-0055){ref-type="ref"}, [56](#jah34745-bib-0056){ref-type="ref"} and future studies will be needed to compare the current results in women. Last, it is unclear what is driving the differences in Wnt gene expression (whether that be genetic or epigenetic variation, or a combination of both). Additional studies should also be performed to assess the impact of Wnt gene expression on other forms of subclinical and clinical disease and outcomes.

We found the expression of 2 circulating Wnt pathway genes, *APC* and *TCF4*, was strongly associated with arterial stiffness, even after adjustment for traditional CVD risk factors. Greater expression of *APC*, a gene involved in downregulating Wnt pathway target gene expression, was associated with greater arterial stiffness; whereas greater expression of *TCF4*, a gene involved in upregulating Wnt pathway target gene expression, was associated with lower arterial stiffness. These human‐derived expression data suggest that Wnt pathway signaling is involved in vascular stiffness and may represent a novel risk factor and pharmacologic target for improving arterial health.
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